87 results about "Cationic liposome" patented technology

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

The invention provides a ginseng exosome anti-aging and anti-oxidation composition and a preparation method thereof, and relates to the field of nursing materials, the ginseng exosome anti-aging and anti-oxidation composition comprises Exo nano-vesicles, procyanidine and cationic liposome, the Exo nano-vesicles are derived from ginseng extracellular fluid, the procyanidine is derived from the cationic liposome, and the cationic liposome is derived from the procyanidine. The ginseng exosome anti-aging and anti-oxidation composition provided by the invention can effectively improve skin wrinkles, enhance skin elasticity, promote collagen synthesis, inhibit collagen degradation and inhibit elastin degradation through the combined action of the Exo nano-vesicles, Pro and cationic lipidosome; degradation of elastin can cause skin to lose resilience, formation of wrinkles is accelerated, and facial skin can be effectively improved and wrinkles can be reduced by promoting synthesis of collagen and inhibiting degradation of elastin.

The present invention belongs to the technical field of cancer immunotherapy, and particularly relates to a cholesterol-modified cationic liposome tumor vaccine, a preparation method therefor, and use thereof. In order to solve the problems of poor targeting and strong side effects of TLR agonists in anti-tumor treatment, the present invention provides a cationic liposome prepared from a cholesterol-modified 1V209 molecule, a cationic lipid component, cholesterol, and DSPE-PEG2000, and then the cationic liposome and ovalbumin 5 form the tumor vaccine by electrostatic adsorption. Animal experiments show that the vaccine can induce antigen-specific CD8+ T cells, activate lymphocytes, and generate stronger antigen cross-presentation, more memory T cells, antibodies, and cytokines. Prophylactic inoculation with the vaccine can significantly delay the progression of mouse melanoma and lymphoma and prolong the survival of mice. The combination use of the vaccine and a PD-1 checkpoint inhibitor can further enhance the anti-tumor effect. Therefore, the vaccine is a promising cancer vaccine.

The invention discloses basic amino acid modified 3S-PCL as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The basic amino acid modified 3S-PCL has a structural formula shown in the specification, wherein R is alkaline amino acid; m, m1 and m2 are all positive integers, and m, m1 and m2 are greater than or equal to 1. According to the invention, a basic amino acid modified three-arm polycaprolactone (3S-PCL) material is designed and synthesized, and the basic amino acid modified three-arm polycaprolactone (3S-PCL) material has good biocompatibility and can be used for lipid nanoparticle nucleic acid delivery instead of a cationic liposome. The preparation method of the basic amino acid modified 3S-PCL material is simple and rapid, and is especially suitable for industrial production. The lipid nanoparticles prepared by using the basic amino acid modified 3S-PCL material as a gene vector can realize efficient delivery of nucleic acid drugs.

The invention discloses an engineered bionic nucleic acid nano diagnosis and treatment agent as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims to solve the problems that an engineered macrophage membrane modified bionic nucleic acid nano diagnosis and treatment agent for oral squamous cell carcinoma is lacked in the prior art, and the curative effect on invasive tumors of the oral squamous cell carcinoma is poor. According to the engineering bionic nucleic acid nano diagnosis and treatment agent, a cationic lipid nucleic acid medicine is wrapped with a macrophage membrane, and PD1 shown as SEQ.ID.NO.1 is stably expressed on the macrophage membrane; the cationic lipid nucleic acid medicine is prepared by loading Cip2a siRNA (small interfering Ribonucleic Acid) on a cationic liposome. The bionic nucleic acid nano diagnosis and treatment agent has a huge application prospect in preparation of oral squamous cell carcinoma diagnosis kits and medicines.

A construction and use of an environmentally adaptive co-regulated mRNA nanodelivery system. By incorporating EACR molecules into mRNA nanoparticles, the microenvironment is remodeled to be suitable for robust and sustained mRNA expression, while tissue damage associated with the self-immunogenicity of mRNA drugs is avoided. The nanodelivery system is compatible with ionizable lipid nanoparticles, cationic liposomes, cationic nanoemulsions, and polymeric nanoparticles. The EACR molecules include: anti-inflammatory drugs, tyrosine kinases / adaptors, JAK / STAT and MAPK pathway inhibitors, nutrients and metabolites, membrane transporters / ion channels, phosphodiesterase and cellular stress inhibitors, and natural viral proteins. The therapeutic mRNAs may encode tumor, viral, or bacterial antigens, immunomodulatory factors, therapeutic antibodies, or functional proteins / enzymes, and can play a role in the fields of regenerative medicine, protein supplementation / replacement therapy, targeted gene editing, and immunotherapy.

The invention belongs to the field of pharmaceutical preparations and cosmetics, and particularly relates to a cationic liposome containing plant extracts as well as a preparation method and application of the cationic liposome. The preparation method comprises the following steps: co-melting or dissolving a cacumen biotae extract, a ginger root extract, a ginseng root extract and a lipid component in a proper organic solvent system, concentrating, adding into a hydration medium, and homogenizing to prepare the cationic liposome containing the plant extract component. According to the invention, the lipid component is taken as a carrier, so that the transdermal performance and bioavailability of the three plant extracts and the active components contained in the three plant extracts can be improved, and the three plant extracts and the active components can penetrate through the cuticle of the skin to the greatest extent, so that the efficacy is effectively exerted.

A vaccine adjuvant, and a preparation method therefor and a use thereof. The vaccine adjuvant is a MA105 immunologic adjuvant, and comprises (1) QS-21:50 μg / ml to 300 μg / ml; (2) Poly I:C: 400 μg / mL to 3000 μg / mL; and (3) lipid molecules constituting a vector, the vector being a mixture of a cationic liposome and a neutral liposome.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a multifunctional bionic nano preparation, a preparation method and application. According to the multifunctional bionic nano preparation, the ginsenoside Rg3 has the dual functions of a medicine and a membrane stabilizer, the platelet membrane has the natural targeting capability on circulating tumor cells and metastases, and meanwhile, the cationic liposome is used for adsorbing negatively-charged NETs nucleic acid protein compounds, so that potential reversal and active targeting are achieved, and the multifunctional bionic nano preparation has a good application prospect. And by co-carrying paclitaxel (PTX) and a photothermal agent (PCP) and integrating photothermal-chemotherapy-immunogenic death (ICD) induction functions, the tumor-related fibroblast activation can be effectively inhibited, circulating tumor cells can be efficiently captured, a tumor immune microenvironment can be remodeled, the tumor cells can be effectively killed, and tumor distal metastasis can be inhibited.

The invention discloses a mannose modified liposome gel microsphere oral delivery system based on cations and application of the mannose modified liposome gel microsphere oral delivery system. The oral delivery system comprises a core layer and a wrapping layer, the core layer is mannose modified cationic liposome loaded with a mucous membrane adjuvant retinoic acid and an antigen, and the wrapping layer is sodium alginate gel vulcanized and modified by cysteine. The mannose modified cationic liposome is prepared by coupling mannose on the surface of the cationic liposome, and the cysteine modified sodium alginate gel is used for protecting antigens in the core layer from being eroded by gastric juice, enhancing the adhesiveness of a delivery system in the intestinal tract and prolonging the retention time of the delivery system in the intestinal tract; in addition, the R-MLip can be expanded and released under the environment that the pH of the intestinal tract is increased. The inside of the gel microsphere of the oral delivery system shows a regular net-shaped structure and has abundant holes and channels, and the oral delivery system shows a good prospect in the aspect of enhancing mucous membrane and systemic immunity and possibly becomes a potential substitute of a traditional attenuated live vaccine in the future.

The invention discloses a periodontal local drug delivery system with antioxidant, anti-inflammatory and antibacterial synergistic effects and a preparation method of the periodontal local drug delivery system, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: firstly, preparing an organic phase from DSPC, cholesterol, SA and resveratrol, and preparing a cationic liposome by taking PBS as a water phase; then preparing a water phase from AlgMA and LAP, taking a surfactant solution as an oil phase, and preparing polydopamine hydrogel microspheres through PDA surface modification; and finally, carrying out physical adsorption loading. Through the synergistic effect of the resveratrol, the cationic liposome and the polydopamine, a periodontitis pathological chain is comprehensively intervened, synergistic treatment is achieved, excellent antibacterial performance, anti-inflammatory effect and antioxidant effect are achieved, the retention rate of the medicine is increased, and the problems that traditional treatment medicine cannot achieve antibacterial, inflammation regulation and oxidative stress synergistic treatment at the same time, and the treatment effect is poor are solved. The residence time of the medicine in the periodontal pocket is short, and frequent administration is needed.

The invention discloses a preparation method and application of a response type cationized two-dimensional nano catalytic transfection agent, and belongs to the field of biology. According to the transfection agent disclosed by the invention, two-dimensional MXene (such as niobium carbide) is taken as a matrix, and the surface of the matrix is sequentially modified with a multi-amino cationic polymer (such as dendritic polyethyleneimine) and aldehyde group polyethylene glycol (CHO-PEG-CHO), so that PNb2C (at) PEG with pH responsiveness is formed. The preparation method comprises the steps of Nb2C nanosheet stripping, PEI cationization, PEG shielding modification and the like. Material characterization shows that the potential of the transfection agent is-12.5 mV (shielding positive charges) when the pH value is 7.4, the potential of the transfection agent is converted into + 14.0 mV (responding to a tumor acidic microenvironment) when the pH value is 6.5, and the transfection agent has the capability of catalyzing decomposition of active oxygen and can protect cells from oxidative damage. Compared with the traditional cationic liposome, the transfection efficiency is equivalent, but the toxicity is obviously reduced, the raw material cost is low, the gene load is high, and the cationic liposome is suitable for the field of gene delivery.

The invention discloses a photosensitizer, dynamic antibacterial hydrogel containing lipidosome wrapping the photosensitizer and a preparation method and application of the dynamic antibacterial hydrogel, and belongs to the technical field of biological materials. The invention provides a novel D-A-D type photosensitizer TPT which is simple in structure and simple in synthetic route, and from the angles of safety, practicability and use specificity of hydrogel dressing, modified hyaluronic acid and modified carboxymethyl chitosan are used as raw materials, cationic liposome wrapping the novel photosensitizer TPT is carried, and the hydrogel dressing is prepared. The efficient antibacterial dynamic cross-linked hydrogel material is prepared. The hydrogel disclosed by the invention has two pH response bonds, namely an imine bond and a boric acid ester bond, and has good moisture retention and biocompatibility; meanwhile, the hydrogel is loaded with the cationic liposome wrapping the novel photosensitizer TPT, so that the hydrogel has excellent active oxygen yield. The hydrogel disclosed by the invention aims to quickly resist bacteria, promote wound healing, reduce infection risk and improve the success rate of treatment through the targeted drug release function of the intelligent hydrogel.

The present invention relates to an mRNA vaccine composition for the prevention of enterovirus A71 (EV-A71) infection. The composition comprises an mRNA encoding the VP1 protein of EV-A71 and lipid nanoparticles (LNPs) comprising specific cationic lipids. Compared with the conventional cationic lipid system, the imidazopyridyl cationic lipid A5 with strong membrane fusion capability is adopted, so that obvious neutralizing antibody and cellular immune response can be induced under single-time and low-dose immune conditions, and excellent safety and children applicability are shown.

The invention discloses an immune agonist and a preparation method thereof, and relates to the technical field of immune agonist preparation, and the preparation method of the immune agonist comprises the following specific steps: S1, preparing a double-target immune agonist monomer; s2, preparing a cationic liposome inner core; s3, biomimetic cell membrane coating; and S4, finished product detection. According to the immune agonist and the preparation method thereof, in the preparation process, a continuous flow microreactor is used for two-step synthesis of a double-target monomer, a segmented precise temperature control mode is matched with microwave strengthening, the reaction period can be shortened, efficient entrapment of the agonist is achieved through a micro-reaction technology, and the problems that a traditional batch method is low in entrapment efficiency and uneven in particle size are solved; in addition, MDC cell membrane extraction is conducted through differential centrifugation, the integrity of the membrane is guaranteed, active targeting of a CD11c marker on the surface of the MDC cell membrane is achieved through a cell biomimetic membrane, and after lipidosome and membrane vesicles with the volume ratio being 3: 1 are fused, the in-vitro BMDC binding rate is increased compared with that of naked lipidosome.

The invention provides ROS (reactive oxygen species)-responsive cationic liposome-loaded tryptanthrin as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ROS response cationic liposome loaded tryptanthrin disclosed by the invention comprises an ROS response cationic liposome and tryptanthrin which is entrapped in the ROS response cationic liposome; the ROS response cationic liposome is prepared from the following raw materials: egg yolk lecithin, cholesterol, DSPE-TK-PEG (distearoyl phosphatidylcholine) and DOTAP (dioctyl phthalate). In view of significant increase of intestinal local active oxygen under the ECLS condition, the ROS-responsive cationic liposome is adopted to wrap tryptanthrin, so that tryptanthrin is selectively released in an intestinal injury area, whole body exposure is reduced, and meanwhile, the protection effect on the intestinal tract is enhanced.

The invention provides a nanoparticle penetrating cornea as well as a preparation method and application thereof. The nanoparticle comprises a cationic liposome G2-C14, an inner core formed by aliphatic polyester and an amphiphilic polymer, and a shell modified by polysaccharide, the hydrophobic drug and the siRNA are loaded in the inner core. According to the nano-particles provided by the invention, through polysaccharide surface modification, ocular surface adhesion and trans-epithelium transport capability are enhanced, multi-barrier penetration of the eye is realized, the nano-particles are effectively delivered to a focus area of posterior segment of the eye, the delivered siRNA targets to silence the expression of age-related macular degeneration pathogenic genes, and the hydrophobic drug removes active oxygen and inhibits release of inflammatory factors, so that the anti-aging effect of the nano-particles is improved. The focus thickness is synergistically reduced.

The invention discloses a method for improving transfection efficiency of chicken primordial germ cells, and belongs to the technical field of cell transfection. The invention provides application of an EGFR (epidermal growth factor receptor) activator NSC 228155 in improvement of plasmid uptake efficiency and cationic liposome transfection efficiency of chicken PGCs, and a method for efficiently transfecting the chicken PGCs is constructed. Experimental results show that compared with a control group, the gene transfection efficiency of the chicken PGCs treated by the EGFR activator NSC 228155 under a DMRIE-C transfection reagent and the gene transfection efficiency of the chicken PGCs treated by the EGFR activator NSC 228155 under a LipofectamineTM 3000 transfection reagent are both remarkably improved, which indicates that the EGFR activator remarkably improves the transfection efficiency of the chicken PGCs; and the EGFR activator does not influence the cell characteristics of the chicken primordial germ cells. The method lays a foundation for establishing an efficient gene editing chicken technical system, and has a wide application prospect.

The invention belongs to the technical field of plant breeding, and discloses a breeding method for improving the mutagenesis efficiency of stem tips of woody plants. The CRISPR-Cas9 ribonucleoprotein complex and plant hormones 6-benzyladenine, gibberellin and jasmonic acid are co-encapsulated and then accurately delivered to stem tip meristem of woody ornamental plants such as acer truncatum, pteroceltis tatarinowii, crape myrtle and tassel, and the gene mutation obtaining rate of the stem tip meristem is effectively increased; the intelligent environment control system is used for dynamically optimizing illumination, temperature, humidity and oxidative stress, activating a plant endogenous DNA repair pathway and further enhancing homologous recombination efficiency, meanwhile, through collaborative optimization of induction hormone signals and environmental stress, the stress resistance is improved, the leaf color, the plant type and the growth vigor can be accurately regulated and controlled, and the yield of the plant is increased. According to the method, efficient, accurate and stress-resistant linked woody plant stem tip mutation breeding is realized.

The invention discloses a multi-chamber vesicle as well as a preparation method and application thereof. Each multi-chamber vesicle is an anionic liposome, and a cavity of the anionic liposome contains a plurality of cationic liposomes and a buffer solution containing Mg < 2 + >. According to the preparation method of the multi-chamber vesicle, a special oil phase and a water phase with different charges are introduced, so that the multi-chamber vesicle in which a plurality of cationic liposomes are wrapped by a single anionic liposome is successfully prepared. The multi-chamber vesicle is good in biocompatibility, controllable in particle size and stable in mechanical property, and provides technical support for preparation of artificial cells and novel drug carriers in the future.

The invention discloses a si-TGM2-loaded macrophage targeting nano-material as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims at solving the problem that a macrophage targeting nano-drug for inhibiting severe acute pancreatitis aiming at a TGM2 target is lacked in the prior art. The technical key points of the invention are as follows: the si-TGM2-loaded macrophage targeting nano material is provided, the si-TGM2-loaded macrophage targeting nano material is a lactoferrin modified cationic lipid nucleic acid drug, and the cationic lipid nucleic acid drug is prepared by coating si-TGM2 as shown in SEQ.ID. NO.1 with a cationic liposome. The si-TGM2-loaded macrophage targeting nanometer material disclosed by the invention has a wide application prospect in preparation of an acute pancreatitis diagnostic kit and a medicine.

Provided are a method for preparing cationic liposomes by using a high-pressure emulsification device, cationic liposomes prepared by the method, and a cosmetic composition, a food composition and a pharmaceutical composition, comprising the cationic liposomes. According to the method for preparing cationic liposomes, toxic organic solvents are not employed and thus it is possible to produce liposomes safe for the skin at mass scale by using a high-pressure emulsification device. In addition, the cationic liposomes prepared by the above method have excellent formulation stability, and are positively charged, so that the skin absorption ability of active ingredients loaded therein may be enhanced. Therefore, the cationic liposomes can be used in cosmetics, foods, drugs, and the like.

The present invention provides a use of paclitaxel cationic liposomes in the manufacture of a medicament for treating terminal solid cancer, a use of paclitaxel cationic liposomes and a systemic therapeutic agent in the manufacture of a medicament for treating terminal solid cancer, and a method for treating terminal solid cancer, in which a therapeutically effective amount of paclitaxel cationic liposomes is administered to a patient with terminal solid cancer, or a therapeutically effective amount of paclitaxel cationic liposomes and a systemic therapeutic agent is administered to a patient with terminal solid cancer.

This invention discloses a basic amino acid-modified 3S-PCL, its preparation method, and its applications, relating to the field of biomedical technology. The structural formula of the basic amino acid-modified 3S-PCL is as follows: [Structure formula would be inserted here]; where R is a basic amino acid; m, m1, and m2 are all positive integers, and m, m1, and m2 ≥ 1. This invention designs and synthesizes a basic amino acid-modified three-armed polycaprolactone (3S-PCL) material, which exhibits good biocompatibility and can replace cationic liposomes for nucleic acid delivery via lipid nanoparticles. The preparation method of this basic amino acid-modified 3S-PCL material is simple and rapid, particularly suitable for industrial production. Lipid nanoparticles prepared using this basic amino acid-modified 3S-PCL material as a gene carrier can achieve highly efficient delivery of nucleic acid drugs.

This invention relates to an oral nanomedicine antigen delivery system and its construction method and application, belonging to the field of oral nanomaterials technology; the construction method includes the following steps: (1) preparation of OM nanoparticle suspension; (2) preparation of cationic liposome suspension; (3) preparation of cationic liposome suspension loaded with OM / BF; (4) construction of oral nanomedicine antigen delivery system. This invention breaks through multiple barriers in the gastrointestinal tract, improves drug bioavailability, and achieves precise immune tracking through the OVA tumor antigen model, simulating in vivo anti-tumor CTL response, thereby exerting anti-tumor effects synergistically at the cellular, tissue, and immune levels, effectively solving the problems of poor water solubility and low delivery efficiency of the active ingredient bufotoxin in traditional Chinese medicine. At the same time, through macrophage-mediated immune regulation and precise drug release, it improves targeting and treatment efficiency, opening up a new avenue for tumor immunotherapy with oral nanomedicine.

This invention discloses a cell preparation targeting bone metastatic tumor cells, its preparation method, and its application, belonging to the field of biomedical technology. The cell preparation comprises senescent neutrophils and drug-loaded cationic liposomes internalized within them. The cationic liposomes encapsulate a STING agonist and a pan-photokinase inhibitor. The preparation method includes: preparing drug-loaded liposomes using a thin-film dispersion-ultrasound method; obtaining senescent neutrophils through in vitro culture of extracted neutrophils; and preparing a senescent neutrophil preparation loaded with liposomes. This invention utilizes the natural bone marrow homing ability of senescent neutrophils to achieve precise targeting of bone metastatic tumor cells, and co-delivers two drugs through liposomes, simultaneously activating anti-tumor immunity and inducing tumor cell apoptosis / autophagy, synergistically treating bone metastases. This system has high drug loading capacity, good encapsulation efficiency, and sustained-release effect, and the preparation process is simple and controllable, providing a new strategy for the treatment of cancer bone metastases.

The application belongs to the technical field of pharmaceutical preparations, and discloses a nano-liposome with synergistic effect of double adjuvants and a preparation method and application thereof.The preparation method of the nano-liposome with synergistic effect of double adjuvants comprises the following steps: (1) mixing manganese chloride solution, cationic liposome, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine-polyethylene glycol, cholesterol and a solvent to react, and evaporating to obtain a lipid film; (2) mixing the lipid film, human unmethylated oligodeoxynucleotide and water to heat, and filtering to obtain the nano-liposome with synergistic effect of double adjuvants.The obtained nano-liposome with synergistic effect of double adjuvants has excellent sustained release property.The obtained nano-liposome with synergistic effect of double adjuvants has stable physicochemical properties after being prepared into a nano-liposome vaccine adjuvant, and is convenient to store and transport.

The invention relates to an anti-ARDS cationic liposome delivery system and application thereof, in particular to an anti-ARDS cationic liposome delivery system and application thereof. The sivelestat sodium carrier is composed of DOTAP, DSPC, polyethylene glycol and cholesterol, and can load two micro RNAs (miR125 and miR223) and a fat-soluble drug sivelestat sodium at the same time. Through TEM (transmission electron microscope detection), Western Blot, real-time fluorescent quantitative PCR and LPS-induced mouse ARDS model pharmacological experiments, it is proved that the material can play a better anti-inflammatory role, the treatment effect is remarkable, and the material has a very good development prospect.

This invention provides an engineered umbilical cord stem cell exosome carrying siCCR5, its preparation method, and its application in the treatment of Alzheimer's disease, belonging to the field of biomedical technology. This invention provides a method for preparing a new drug for treating Alzheimer's disease. First, a lipid membrane is prepared, then the lipid membrane is dissolved, and siCCR5 and umbilical cord mesenchymal stem cell exosomes are added. The siCCR5 is then delivered into the umbilical cord mesenchymal stem cell exosomes using a cationic liposome extrusion method, resulting in engineered umbilical cord stem cell exosomes carrying siCCR5. The engineered exosomes prepared by this invention can repair brain tissue through tissue regeneration and regulate the brain microenvironment without producing toxic side effects on the body. Furthermore, the engineered exosomes carrying siCCR5, which targets specific genes, have stronger targeted therapeutic efficacy than ordinary hUCMSC-EVs, and can more effectively exert anti-inflammatory effects, improving the progression of Alzheimer's disease.